Abstract: | Infliximab is a tumor necrosis factor‐alpha (TNF‐a) inhibitor widely used in the treatment of moderate to severe chronic plaque psoriasis. Here, we report a case of vitiligo following infliximab administration in a patient with chronic plaque psoriasis. The case serves as a reminder of vitiligo induced by TNF‐a‐antagonist therapy. |